		Schedule 2 - Latvia  Article 2 - Section 2.03  Date of p												
		Full Name HCPs: City of Principal Practice HCOs: city where registered Country of F			Principal Practice Address	Unique country local identifyer OPTIONAL	Donations and	Contribution to costs of Events			Fee for service and consultancy		Transfers of Value re Research &	
							Grants to HCOs	Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accomodation	Fees	Related expenses agreed in the fee for service or consultancy contract	n Development as defined (Art. 3.04)	Total
		INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
	l "	Tolmane, leva	Riga	Latvia	Linezera iela 3		N/A	N/A	0,00	0,00	923,08	0,00		923,08
	HCPs	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
		Aggregate amount attributable to transfers of value to such Recipients					N/A	N/A						
_		Number of Recipients (named list, where appropriate)					N/A	N/A						
Ā		% of total transfers of value to individual HCPs					N/A	N/A						
NDIVID			(i.	e. all transfers of valu	ıe during a year for an individual HC		NAMED DISCLOSURE mization should be av		ipient or public autho	rities' consultation o	nly, as appropriate)			
_	s	Latvian Adults Society of Rheumatology	Riga		Baltic Travel Group, Elizabetes Street 31	LV40003482252	0,00	1500,00	0,00	0,00	0,00	0,00		1500,00
	SO				OTHER, NOT INC	LUDED ABOVE - where in	formation cannot be	disclosed on an individual basi	s for legal reasons					
		Aggregate amount attributable to transfers of value to such Recipients												
		Number of Recipients (named list, where appropriate)												
		% of total transfers of value to individual HCC	Os											
99	3 8				- 6 601		AGGREGATE DISCLO							
≪ ≃	2 4	Transfer of Value re Research and Development as defined - Article 3.04 and Schedule 1												0,00